Related Experiment Video
Updated: Jun 8, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[153Sm-EDTMP in the treatment of bone metastasis of lung cancer]
1Department of Nuclear Medicine , The First University Hospital , West China University of Medical Sciences , Chengdu , Sichuan 610041 , P. R. China.
Background:
To explore the clinical effect of 153Sm-EDTMP therapy in the treatment of bone metastasis of lung cancer.
Methods:
One hundred and ten patients with painful bone metastasis were entered into this study. The patients were administrated with two steps. At first , they were injected with tracer dose of 153Sm-EDTMP. After a series of index were calculated , such as urine discharge , bone uptake , cumulated skeletal activity , absorbed dose of red marrow and total dose , the second injection was given.
Results:
Of 110 cases , 98 (89. 1 %) experienced pain relief with complete response in 38 cases and partial response in 60 ones. Pain relief occurred from 3 h to 4 weeks (7. 5 d +/-6. 3 d) . Duration of pain relief from single injection ranged from 2 to 4 weeks. Follow-up imaging studies were performed within 3 months. In 12 cases , metastatic foci disappeared completely (CR) , Karnofsky score increased by 20 , and analgesic were discontinued. In 20 patients , both number and diameter of metastatic foci decreased (PR) , with an improvement in Karnofsky score ranging from 10 to 15. There were significant decreases in WBC and platelet count found in 35 of 110 patients after therapy , however , blood cell counts returned to baseline within 1 to 3 months.
Conclusions:
153Sm-EDTMP has proven to be a safe and effective therapy for bone pain in lung cancer , and often results in shrinkage or disappearance of metastatic foci.
